image credit: Freepik

Merck will pay royalties on next-gen pneumococcal shot to settle Pfizer patent fight

September 24, 2021


Even before Merck and Pfizer won back-to-back FDA nods for their rival pneumococcal conjugate vaccines this summer, the companies were fighting it out in court over patents on the lucrative shots. With a new settlement, the pharma rivals are putting that dispute to rest.

In a settlement this week in the U.S. federal court in Delaware, Merck and Pfizer agreed to dismiss patent claims against one another. Under the deal, Merck will pay Pfizer 7.25% of its net sales from pneumococcal conjugate shots worldwide through the end of 2026, Bloomberg reports.

Read More on FiercePharma